Overexpression of long non-coding RNA cancer susceptibility 2 inhibits cell invasion and angiogenesis in gastric cancer

Abstract

Increasing evidence has indicated that long non-coding RNAs (lncRNAs) were aberrantly expressed and acted as key regulators in various types of disease, including cancer. lncRNA cancer susceptibility 2 (CASC2) has been found to be downregulated and acts as a tumor suppressor in various type of cancer, including gastric cancer (GC). However, the precise function of lncRNA CASC2 in GC remains unclear. In the present study, the expression level of lncRNA CASC2 in GC was investigated and the molecular mechanisms by which CASC2 acted as a tumor suppressor in this disease were elucidated. It was found that the expression level of lncRNA CASC2 was decreased, which correlated with TNM stages, vessel invasion, metastasis, and overall survival of patients with GC. Furthermore, overexpression of CASC2 inhibited the invasion and angiogenesis of GC cells. Thus, the present study indicated the important roles and underlying molecular mechanisms of lncRNA CASC2 on GC, and indicated that lncRNA CASC2 may present as a potential therapeutic target for the treatment of GC.

RETRACTED ARTICLE: LncRNA CASC11 promoted gastric cancer cell proliferation, migration and invasion in vitro by regulating cell cycle pathway

“…Long non-coding RNAs (lncRNAs) are a class of single-stranded RNA molecules which have no protein-coding capacity [7]. In the last few days, investigators discovered that LncRNA can participate in many important biological processes [8][9][10].…”

Long non‑coding RNA CASC2 inhibits progression and predicts favorable prognosis in epithelial ovarian cancer

“…Since then, further studies in other types of neoplasia have been conducted, and the mechanisms and the interactions of CASC2 in cancer have been better elucidated (35); in addition, CASC2 has become synonymous with CASC2a. Aberrant expression of CASC2 was detected in renal cell carcinoma (12), osteosarcoma (36), pancreatic cancer (13), endometrial cancer (6), hepatocellular carcinoma (37), glioma (10,38,39), non-small cell lung cancer (8) and gastric cancer (11). Functionally, Table II.…”

“…Cancer susceptibility candidate 2 (CASC2), an lncRNA located at chromosome 10q26, was originally identified as a downregulated gene in endometrial cancer (6). Previous studies suggested that CASC2 may act as a tumor suppressor gene, with epigenetic and genetic alterations contributing to gene inactivation (6)(7)(8)(9)(10)(11)(12)(13). Downregulation of CASC2 may provide a growth advantage in EOC cells (7).…”

“…Downregulation of CASC2 may provide a growth advantage in EOC cells (7). Recent studies identified that CASC2 is associated with tumor development and prognosis in various cancer types, including renal cell carcinoma, osteosarcoma, bladder cancer, pancreatic cancer, endometrial cancer, hepatocellular carcinoma, glioma, non-small cell lung cancer and gastric cancer (8)(9)(10)(11)(12)(13). However, little is known regarding the role of CASC2 in EOC.…”

Low Expression of LncRNA Cancer Susceptibility Candidate 2 and its Clinical Significance in Cancer Tissues

“…These cancers ranged from an early stage to advanced clinical stages (I, II, III, and IV). Of the 8 studies, 3 included a follow-up of greater than or equal to 60 months [23, 27, 28]; the remaining 5 studies covered less than 5 years [21, 22, 24-26]. The expression of lncRNA CASC2 in all eligible studies was measured by quantitative real-time polymerase chain reaction (qRT-PCR) and normalized relative to GAPDH or RNU6B using the 2 –ΔΔCt method.…”